Prosecution Insights
Last updated: November 08, 2026
Application No. 18/465,823

CXCR4 INHIBITORS AND USES THEREOF

Non-Final OA §112§DOUBLEPATENT
Filed
Sep 12, 2023
Priority
Jun 21, 2016 — provisional 62/352,820 +5 more
Examiner
JAVANMARD, SAHAR
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
X4 Pharmaceuticals Inc.
OA Round
1 (Non-Final)
65%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 65% — above average
65%
Career Allowance Rate
490 granted / 754 resolved
+5.0% vs TC avg
Strong +34% interview lift
Without
With
+34.1%
Interview Lift
resolved cases with interview
Typical timeline
2y 10m
Avg Prosecution
58 currently pending
Career history
800
Total Applications
across all art units

Statute-Specific Performance

§101
1.2%
-38.8% vs TC avg
§103
46.7%
+6.7% vs TC avg
§102
14.6%
-25.4% vs TC avg
§112
16.2%
-23.8% vs TC avg
Black line = Tech Center average estimate • Based on career data from 754 resolved cases

Office Action

§112 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the Claims This Office Action is in response to Applicant's Restriction Requirement remarks filed on July 1, 2026. Claim(s) 36-55 are pending. Claim(s) 36-53 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Applicant's election of Group III drawn to a method of treating a primary immune deficiency disease or disorder and election of species of compound I-1 (compound) and WMIH (disease) without traverse of the restriction requirement in the reply is acknowledged. The requirement is deemed proper and is therefore made FINAL. Claim(s) 54-55 are examined herein insofar as they read on the elected invention and species. The elected species was found free of the art, therefore the search was expanded to a genus encompassing formula I in its entirety. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the claims at issue are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the reference application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The USPTO internet Web site contains terminal disclaimer forms which may be used. Please visit http://www.uspto.gov/forms/. The filing date of the application will determine what form should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to http://www.uspto.gov/patents/process/file/efs/guidance/eTD-info-I.jsp. Claims 54-55 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 10,759,796. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are to treating a primary immune deficiency disease as recited in claim 54 comprising administering a compound of formula I. The patented claims are drawn to a compound of formula I of the same scope. While the patented claims are product claims, they must have utility as they are utility patents. To understand the utility of the compounds, Examiner went to the specification for guidance. Since the scope of the compounds/compositions of the instant invention is the same as of said patent and their utilities are the same, then the instant application is obvious over said patent. A later claim in a patent to a method of treatment using a compound is not patentably distinct from a claim to the identical compound in a first patent disclosing the identical use. See Geneva Pharmaceuticals, Inc. v. GlaxoSmithKline PLC, 349 F.3d 1373 (Fed. Cir. 2003); Pfizer, Inc. v. Teva Pharmaceuticals USA, Inc., 518 F.3d 1353, 1363 (Fed. Cir. 2008); Sun Pharmaceutical Industries, Ltd. v. Eli Lilly & Co., 611 F.3d 1381 (Fed. Cir. 2010). Thus, the invention as a whole would have been prima facie obvious to one of ordinary skill in the art at the time it was made. Claims 54-55 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claim 1-15 and 20-21 of U.S. Patent No. 11,306,088. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are to treating a primary immune deficiency disease as recited in claim 54, which are CXCR4-mediated, comprising administering a compound of formula I. The patented claims are drawn to a method of treating a CXCR4-mediated disease, disorder, or condition, comprising administering to a patient in need thereof a compound of Formula Ia. Patented Formula I and formula I of the instant claims are of the same scope. Patented claim 20 is drawn to treating the same CXCR4-mediated diseases including a primary immune deficiency selected from: warts, hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome; severe congenital neutropenia (SCN); GATA2 deficiency (Mono MAC syndrome); idiopathic CD4+ T lymphocytopenia (ICL); or Wiskott-Aldrich Syndrome. Thus, the two inventions overlap greatly in scope. Claims 54-55 are rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1-11 of U.S. Patent No. 11,780,837. Although the conflicting claims are not identical, they are not patentably distinct from each other because the instant claims are to treating a primary immune deficiency disease as recited in claim 54 comprising administering a compound of formula I. The patented claims are drawn to a compound of formula IX. Patented formula IX is embraced in formula I of the instant claims, namely when A is a pyridyl ring. While the patented claims are product claims, they must have utility as they are utility patents. To understand the utility of the compounds, Examiner went to the specification for guidance. Since the scope of the compounds/compositions of the instant invention is the same as of said patent and their utilities are the same, then the instant application is obvious over said patent. A later claim in a patent to a method of treatment using a compound is not patentably distinct from a claim to the identical compound in a first patent disclosing the identical use. See Geneva Pharmaceuticals, Inc. v. GlaxoSmithKline PLC, 349 F.3d 1373 (Fed. Cir. 2003); Pfizer, Inc. v. Teva Pharmaceuticals USA, Inc., 518 F.3d 1353, 1363 (Fed. Cir. 2008); Sun Pharmaceutical Industries, Ltd. v. Eli Lilly & Co., 611 F.3d 1381 (Fed. Cir. 2010). Thus, the invention as a whole would have been prima facie obvious to one of ordinary skill in the art at the time it was made. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 54 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112(pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, claim 54 recites the broad recitation “severe congenital neutropenia (SCN)”, and the claim also recites “those arising from G6PC3 deficiency, GATA2 deficiency (Mono MAC syndrome), idiopathic CD4+T lymphocytopenia (ICL); and Wiskott-Aldrich Syndrome”, which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Amending the claims by deleting the terms (preferably …) would obviate the rejection. Conclusion Claims 54-55 are not allowed. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sahar Javanmard whose telephone number is (571)270-3280. The examiner can normally be reached on Monday-Friday, 9:00-5:00 EST. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached on 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. /SAHAR JAVANMARD/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Sep 12, 2023
Application Filed
Sep 09, 2026
Non-Final Rejection mailed — §112, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12774280
NOVEL SUBSTITUTED TRICYCLIC AZA-HETEROCYCLES AS SOS1 INHIBITORS
3y 1m to grant Granted Oct 27, 2026
Patent 12766151
TESTOSTERONE COMPOSITIONS
4y 5m to grant Granted Oct 20, 2026
Patent 12758603
CANNABIDIOLIC ACID (CBDA) DERIVATIVES AND USES THEREOF
3y 10m to grant Granted Oct 13, 2026
Patent 12760019
Novel SIK Inhibitors
3y 1m to grant Granted Oct 13, 2026
Patent 12751945
COMPOUND FOR THE TREATMENT AND PREVENTION OF CENTRAL NERVOUS SYSTEM DISORDERS
4y 3m to grant Granted Oct 06, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
65%
Grant Probability
99%
With Interview (+34.1%)
2y 10m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 754 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month